Pocared EIB Event
Pocared EIB Event
Pocared Diagnostics secures a EUR 22 million EIB backing for completion of the development and commercialization of its rapid testing system
First-EIB-support-for-medtech-investment-in-israel
POCARED Diagnostics Secures $50 Million Capital Commitment From GEM as Company envisages going public via SPAC merger
POCARED announced that it has signed an agreement with GEM Global Yield LLC SCS ("GEM")
POCARED Diagnostics Ltd. will be presenting at ASM Microbe 2019 in San Francisco
Poster presentation: Saturday Jun 22, 2019. 11 am-12 pm and 4 pm - 5 pm.
POCARED Diagnostics Ltd. Announces Real time Identification of Bacterial Species and Antibiotic Resistance Markers
a leading in-vitro diagnostic and pre-analytical technologies manufacturer announces a breakthrough in real time identification of bacterial species and antibiotic resistance markers utilizing its proprietary technology in the P 1000.
POCARED Diagnostics Ltd. Presents a Novel Gram Stain Methodology
Introducing the first system that can perform both direct, automated Gram staining and sample concentration.
POCARED Diagnostics Ltd. closed another $15 Million in funding
The company raised an additional $15 million (milestone-based) in funding to complete its clinical trials and increase manufacturing capacity while preparing to commercialize both the POCARED P-1000TM and SP platforms.
POCARED Diagnostics Ltd. appoints Mr. Edward J. Ludwig to its Board of Directors
Mr. Ludwig is former Chairman of the Board, President and Chief Executive Officer of BD (Becton, Dickinson and Company) (NYSE:BDX), a global medical technology company headquartered in Franklin Lakes, New Jersey.